Bora Pharmaceuticals Sustainability Profile
Bora Pharmaceuticals, headquartered in California, is a prominent player in the pharmaceutical industry, specialising in contract development and manufacturing services. Founded in 2010, the company has rapidly expanded its operational footprint, with significant facilities in North America and Asia, catering to a global clientele. Bora Pharmaceuticals is renowned for its expertise in the development and production of complex dosage forms, including solid oral, semi-solid, and liquid formulations. Their commitment to quality and innovation has positioned them as a trusted partner for pharmaceutical companies seeking reliable manufacturing solutions. With a focus on enhancing patient outcomes, Bora Pharmaceuticals has achieved notable milestones, including successful collaborations with leading pharmaceutical firms. Their dedication to excellence and customer satisfaction continues to solidify their reputation in the competitive landscape of pharmaceutical manufacturing.
DitchCarbon Score
How does Bora Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bora Pharmaceuticals's score of 57 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bora Pharmaceuticals's reported carbon emissions
In 2024, Bora Pharmaceuticals reported total carbon emissions of approximately 28,830,000 kg CO2e, with Scope 1 emissions at about 8,836,617 kg CO2e and Scope 2 emissions at approximately 19,993,380 kg CO2e. Additionally, Scope 3 emissions from employee commuting were about 5,474,498 kg CO2e. This represents a decrease from 2023, where total emissions were approximately 34,304,491 kg CO2e, with Scope 1 at about 8,836,620 kg CO2e and Scope 2 at approximately 19,679,820 kg CO2e. Bora Pharmaceuticals has set ambitious climate commitments, aiming to reduce Scope 1 and Scope 2 emissions by 30% by 2030, using 2023 as the baseline year. The company began implementing ISO 14064 greenhouse gas inventories in 2021 and has engaged a third-party institute for verification. This initiative is part of their broader strategy to enhance sustainability across their operations. The emissions data is not cascaded from any parent organization, indicating that Bora Pharmaceuticals is independently managing its carbon footprint and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 12,649,345.4 | 00,000,000.0 | 0,000,000 | 0,000,000.0 |
| Scope 2 | 10,015,185.2 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 21,525,110.2 | - | - | 0,000,000.0 |
How Carbon Intensive is Bora Pharmaceuticals's Industry?
How Carbon Intensive is Bora Pharmaceuticals's Location?
Bora Pharmaceuticals's Scope 3 Categories Breakdown
Bora Pharmaceuticals's Scope 3 emissions, which decreased by 75% last year and decreased by approximately 75% since 2021, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 16% of total emissions under the GHG Protocol, with "Employee Commuting" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Bora Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bora Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
